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Abstract
Esophageal squamous cell carcinoma (ESCC) is a deadly disease that requires extensive research. 
In this review, we update recent progress in the research area of targeted therapy for ESCC. Sox2 
and its associated proteins (e.g., ΔNp63α), which regulate lineage survival of ESCC cells, are 
proposed as therapeutic targets. It is believed that targeting the lineage-survival mechanism may be 
more effective than targeting other mechanisms. With the advent of a new era of personalized 
targeted therapy, there is a need to move from the tumor-centric model into an organismic model.
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Esophageal cancer is the eighth most prevalent cancer in the world. Each year, there are 
more than 480,000 incipient cases and 400,000 deaths, with more than 80% occurring in 
developing countries.1 Esophageal squamous cell carcinoma (ESCC) is the predominant 
histologic type worldwide. In China alone, more than 280,000 new cases and 200,000 deaths 
were estimated in 2010.2 Despite many advances in diagnosis and treatment in the past 
decades, the 5-year survival rate for patients with esophageal cancer ranges from 15% to 
20%.3 This is mainly due to late diagnosis, aggressiveness of this cancer, and a lack of 
effective treatment strategies.4
Surgery remains the mainstay of treatment for ESCC, although surgery alone achieves poor 
locoregional control and poor long-term outcome. The 5-year survival rate for non-
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metastatic ESCC is 10–40% if treated with surgery alone.5 Unfortunately, esophagectomy 
itself is a complex procedure with significant morbidity and mortality. Two percent to 25% 
of patients die within 30 days after surgery.5 Since 40–50% of surgical cases have stage III 
disease,4,6,7 most patients are given neoadjuvant chemotherapy with cisplatin/fluorouracil 
and carboplatin/paclitaxel. A recent meta-analysis showed a significant improvement in 
overall survival after neoadjuvant chemotherapy, with a 13% reduction of relative mortality 
risk and a 5.1% increase in 2-year survival. However, the difference was not statistically 
significant.7 More than 50% of patients with ESCC present with unresectable or metastatic 
disease at the time of diagnosis.4 Chemoradiotherapy is preferred as a nonsurgical approach 
if there are no contraindications. This combination approach yields a superior palliative 
outcome compared to radiotherapy alone and improves long-term progression-free survival,8 
although its efficacy in locoregional control is inferior to surgery.9 For chemotherapy, 
fluorouracil and cisplatin with or without a third drug (such as epirubicin or taxane) is 
known as the most efficacious combination.10 Approximately 40% of patients for whom 
first-line treatment fails will be potential candidates for second-line therapy.11 Unfortunately, 
salvage choices of second-line therapy are sparse, and there is no consensus on the 
optimum.10 Survival of these patients is poor, with a median survival of 5–10 months.12–22
ESCC genomics: an update
Recently, tremendous progress has been made in cancer genomics and epigenomics with the 
advent of high-throughput techniques like next-generation sequencing. Four groups have 
reported the genetic landscape of human ESCC with whole-genome and exome 
sequencing.23–26 On the basis of these studies, we have proposed a strategy of personalized 
targeted therapy for ESCC.27
Several reports on genomic alterations in human ESCC have been published this year using 
samples from China and Japan.28–35 In addition to single-nucleotide variants, copy-number 
alterations, and alterations of multiple signaling pathways in human ESCC, these studies 
further demonstrated (1) genomic alterations in a precancerous lesion, atypical hyperplasia; 
(2) mutual exclusivity of NOTCH1 and PIK3CA mutations; (3) structural variations, 
including deletions and translocations through non-homologous end joining or alternative 
end-joining mechanisms and local chromosomal misarrangements through the mechanisms 
of chromothripsis, kataegis, and breakage–fusion bridge. Contributions of individual genes 
or pathways to carcinogenesis and prognosis were further analyzed in vitro and in vivo. 
Diagnostic, preventive, and therapeutic applications are proposed as future research 
directions. Targeted sequencing of a cancer gene panel was also applied to human ESCC, to 
improve cost-effectiveness.36
On the other hand, the outcome of targeted therapy guided by the genomic alterations 
remains disappointing. Using EGFR as an example, clinical trials of targeted therapy have 
only shown limited success in improving the overall survival of patients with ESCC.37,38 
Resistance shows up in cancer cells during the treatment, through multiple mechanisms. 
Combinations of multiple targeting agents may offer some small advantages.39,40 Off-label 
use of targeting agents based on tumor molecular profiling has not been shown to improve 
progression-free survival.41
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The lineage-survival mechanism as a target
Among the single-nucleotide variants, copy-number alterations, and alterations of multiple 
signaling pathways, SOX2 amplification is clearly a cancer driver leading to ESCC.26 In 
fact, before these studies, SOX2 was found to be an amplified oncogene at chromosome 
3q26 in human ESCC by two independent groups.42,43 As a member of the Sox family of 
transcription factors, SOX2 plays a critical role in maintaining embryonic stem cells, as well 
as adult stem cells, in multiple tissues. During fetal development, SOX2 plays major roles in 
ectodermal, endodermal, and mesodermal development. SOX2 deficiency causes multiple 
human diseases, including anophthalmia–esophageal–genital syndrome. After birth, SOX2 
expression remains in some adult tissues and cells. It continues to play critical roles in adult 
tissue homeostasis, regeneration, reprogramming, and pathogenesis.44 The functional role of 
SOX2 in carcinogenesis has been extensively reviewed by multiple groups.45–47
In human ESCC, SOX2 is amplified in ~15% of cases and overexpressed in ~70% of cases, 
suggesting that multiple mechanisms other than amplification can lead to SOX2 
overexpression. SOX2 overexpression is significantly associated with higher histological 
grade and poorer clinical survival of ESCC patients.48,49 Functionally, transgenic SOX2 
overexpression drives the complete process of squamous cell carcinogenesis in the mouse 
forestomach.50 On the contrary, mice with hypomorphic SOX2 exhibit an esophagus lined 
by a columnar epithelium instead of a keratinized stratified squamous epithelium, suggesting 
an essential role of SOX2 in esophageal epithelial development.51 SOX2 is indeed an 
amplified lineage-survival oncogene in ESCC,42 as evidenced by its crucial role in 
esophageal squamous epithelial cell proliferation and survival during development, its 
overexpression in squamous epithelial cells of ESCC, its amplification in a subset of ESCC, 
its essential role for ESCC survival, and its function as a transcription factor.52 This 
discovery provides a possibility for developing targeted therapy of ESCC, even though 
targeting a transcription factor is a technical challenge. However, recent technical advances 
have improved the druggability of transcription factors.53
As a transcription factor, SOX2 has a DNA-binding transcription domain and functional 
domains that interact with other cofactors. Eighty-two SOX2-associated nuclear proteins 
have been identified in two human ESCC cell lines (KYSE70 and TT) using tandem affinity 
purification followed by liquid chromatography–tandem mass spectrometry.54 This list 
includes CBX3, DNMT1, HDAC2, KDM1A, KLF5, PARP1, TP63, and many other 
proteins. Among these, the most interesting is TP63, which is encoded by the p63 gene 
located ~7 Mb from Sox2. These two genes are often co-amplified in multiple cancers (Fig. 
1A & 1B). It is known that SOX2 directly regulates transcription of p63 in lung cancer and 
lung basal cells.42,55 About 20% of ESCC cases harbor p63 gene amplification and ~60% 
overexpression.56–58
The predominant isoform of TP63 in the basal cells of the esophageal epithelium is known 
as ΔNp63α. Similar to SOX2, ΔNp63α drives carcinogenesis via multiple mechanisms.59,60 
It may antagonize the transcriptional activity of TAp73 and the p73-dependent proapoptotic 
transcriptional program61,62 and modulate expression of its target genes through physical 
interactions with HDAC1/2 and the histone H2A.Z.63–65 Silencing of ΔNp63α in ESCC 
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cells inhibited cell proliferation and colony formation via downregulation of Akt signaling.66 
Overexpression of ΔNp63α in squamous epithelial cells in transgenic mice leads to 
increased suprabasal cRel, Ki-67, and cytokine expression, together with epidermal 
hyperplasia and diffuse inflammation.67 On the contrary, TP63 knockout mice exhibit an 
esophageal phenotype similar to that seen in SOX2 hypomorphs.68 These data suggest that 
ΔNp63α is also an amplified lineage-survival oncoprotein for ESCC.
In contrast to proteins directly associated with lineage survival (e.g., ΔNp63α), other SOX2-
associated proteins in ESCC appear to regulate gene expression and may also be associated 
with lineage survival. CBX3 regulates RNA processing genome-wide, and loss of CBX3 
leads to dramatic accumulation of unspliced nascent transcripts and alterations in target gene 
expression.69 DNMT1 contains a DNA methyltransferase domain at its C-terminus for 
maintenance of global CpG methylation patterns and a large N-terminal domain for protein–
protein interactions.70 KLF5 regulates proliferation, apoptosis, and invasion in ESCC cells. 
Loss of KLF5 in the context of TP53 deletion drives invasive progression of ESCC, and 
restoration of KLF5 leads to apoptosis and suppresses cell survival.71,72 PARP1 interacts 
with and poly(ADP-ribosyl)ates SOX2 directly for degradation of SOX2 protein. As a result, 
PARP1 knockout enhances SOX2 expression and modifies cell differentiation.73–75 HDAC2 
regulates expression of SOX2, and HDAC1/2 deficiency leads to loss of SOX2 expression 
and blocks proximal airway development.76 HDAC1/2 also controls the transcriptional 
activity of ΔNp63α.77
Genes and signaling pathways upstream or downstream of SOX2 have been extensively 
studied in the literature.45,47 However, cancer therapy targeting signaling pathways is known 
to be associated with a high rate of resistance, and resistance is predicted to appear in ESCC 
patients as well.27 It may be less desirable to target SOX2 upstream or downstream 
signaling, even though targeting the downstream Akt/mTOR or IL6/STAT3 pathways seems 
to be effective.43,50 The high rate of resistance to targeted therapy has prompted the cancer 
research community to consider combination therapy (i.e., targeting multiple targets or 
pathways).39,40 Alternatively, transcription factors or regulators are potentially better 
therapeutic targets, simply because these transcription factors define the cancer phenotype.78 
Here, we argue that targeting the lineage-survival mechanism in ESCC cells is potentially 
more potent and less likely to produce resistance than targeting other signaling pathways. 
Four approaches are potentially applicable for ESCC: (1) using small interfering RNA 
(siRNA) to target SOX2 and/or ΔNp63α, although this approach is not feasible at this time; 
(2) enhancing the immune reaction against cancer cells with overexpressed SOX2 and 
ΔNp63α participate; and (4) targeting epigenetic modifications in which SOX2 and ΔNp63α 
are involved.
SOX2 itself has been targeted by vaccines79,80 and zinc finger–based artificial proteins.81,82 
SOX2-associated proteins have been targeted as well. For example, specific inhibitors of 
KDM1A/LSD1, a SOX2-associated protein, selectively impair the growth of SOX2+ lung 
squamous cell carcinoma, but not that of SOX2− cells. Inactivation of KDM1A reduces 
SOX2 expression, promotes G1 cell cycle arrest, and induces genes for differentiation by 
selectively modulating the methylation states of H3K4 and H3K9.83 It would be very 
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intriguing to target protein–protein interactions in which SOX2 and ΔNP63α are involved, 
with lineage survival as the readout.
There are two major concerns with regard to targeting SOX2 and/or ΔNP63α in ESCC. 
First, these genes are normally present in both normal tissue and cancer. Targeting the 
SOX2–ΔNP63α interaction may potentially alleviate the concern of side effects, because not 
many adult tissues coexpress these two proteins (only the larynx, bronchiole, tongue, 
esophagus, anus, tonsil, and exocervix).84,85 Second, there is a possibility of inducing 
phenotype switching of cancer cells (i.e., transdifferentiation of ESCC cells into 
adenosquamous cells or even adenocarcinoma cells), as loss of SOX2 and p63 is an early 
event in intestinal metaplasia of the esophageal squamous epithelium.86 This approach may 
also potentially select poorly differentiated, lineage-independent cancer cells.52
Targeting the lineage-survival mechanism requires a deep understanding of SOX2–ΔNP63α 
biochemistry and its interaction with other factors. The SOX2–ΔNP63α interactome in 
ESCC needs to be further clarified with better techniques, for example, stable isotope 
labeling using amino acids in cell culture. Biological replicates with forward and reverse 
experiments are needed to enhance confidence in protein interactions.87 The functional roles 
of SOX2/ΔNP63α-associated proteins in lineage survival need to be well understood. High-
throughput screening has been used to screen inhibitors of protein–protein interactions. 
Although a few successes have been reported in the literature, classical target-based drug 
discovery using small molecules is challenging, in particular when the interactions involve 
multiple proteins.88,89 Recently, technical advances have been made in this area.90 For 
example, in silico modeling of protein–protein interactions has been successfully used to 
identify raloxifene and bazedoxifene as novel inhibitors of the IL6/GP130 interaction.91 
With the well-characterized ESCC cell lines (KYSE series and TE series) and a SOX2-
transgenic mouse model of ESCC,43,50 it is believed that potent agents will be developed for 
treatment of SOX2-overexpressing ESCC.
The organismic model in ESCC treatment and its implications
With the advent of personalized targeted therapy, there is a need to move from the tumor-
centric model into an organismic model.92 According to this model, clinicians need to 
consider not only the tumor itself but also its microenvironment and the whole body (Fig. 2). 
The idea that “there is an order in cancer” suggests that homeostatic mechanisms in the 
tumor have to be taken into consideration in targeted therapy.93 The tumor 
microenvironment has been investigated for years for its capability to both promote and 
restrain cancer.94 However, its potential use in ESCC treatment has not been well studied 
(see a recent review in Ref. 95). Antiangiogenesis and immune therapy targeting the 
microenvironment are currently under clinical investigation. At the organismic level, it is far 
more complex. Intriguing questions may be asked: how the body reacts to the tumor, how 
the tumor reacts to the body, and how to manipulate the body against the tumor and its 
microenvironment.
Nevertheless, this organismal model has multiple implications. Our therapeutic goal may 
turn into “keeping clinical cancer under control and living with microscopic cancer.” The 
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mindset of “5-year survival” may give away to “life-time treatment and monitoring.” 
Surgical resection, which is currently the mainstay for ESCC treatment, needs to be more 
precise and less invasive, and may need to be repeated over the course of treatment. 
Monitoring disease progression will be of critical significance. Emerging techniques, such as 
circulating tumor cells and DNA, will be essential in monitoring therapeutic response and 
disease status.96,97 There will be a great need to mitigate the various side effects of targeted 
therapy in order to improve the quality of life. The variety of issues (e.g., financial, social, 
psychological, behavioral) will make decision making in ESCC treatment sophisticated.
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(A) SOX2 and (B) TP63 amplification in human cancers. Data are obtained from the TCGA 
database (www.cbioportal.org). Only cancers with a high incidence of gene amplification (> 
5%) are included. There is an obvious overlap between SOX2 and TP63 amplification in 
these cancers.
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An organismic model of ESCC, as opposed to the tumor-centric model, calls for attention to 
the organism and the tumor microenvironment.
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